🟢 Ironwood Pharmaceuticals is trading 6% up today on positive apraglutide trial results and technical momentum

Ironwood Pharmaceuticals is trading 6% up at $4.45, extending a sharp rebound following promising trial results for its IBS-C drug, apraglutide.

• The move follows weekend reports highlighting positive clinical data, which helped the stock recover into the $4.20–$4.30 range and attracted aggressive dip-buying.
• Current gains are being driven by strong technical momentum and a broader risk-on market sentiment after a period of recent volatility.